🇺🇸 High-Dose Dexamethasone in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Cardiac Arrest — 1 report (10%)
- Cytokine Release Syndrome — 1 report (10%)
- Dizziness — 1 report (10%)
- Dyspnoea — 1 report (10%)
- Hepatitis Acute — 1 report (10%)
- Immune Effector Cell-Associated Neurotoxicity Syndrome — 1 report (10%)
- Motor Dysfunction — 1 report (10%)
- Muscular Weakness — 1 report (10%)
- Myelitis — 1 report (10%)
- Pneumonia — 1 report (10%)
Other Immunology, Rheumatology, Endocrinology approved in United States
Frequently asked questions
Is High-Dose Dexamethasone approved in United States?
High-Dose Dexamethasone does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for High-Dose Dexamethasone in United States?
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno is the originator. The local marketing authorisation holder may differ — check the official source linked above.